Cargando…

RAS, Cellular Plasticity, and Tumor Budding in Colorectal Cancer

The high morbidity and mortality of colorectal cancer (CRC) remain a worldwide challenge, despite the advances in prevention, diagnosis, and treatment. RAS alterations have a central role in the pathogenesis of CRC universally recognized both in the canonical mutation-based classification and in the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maffeis, Valeria, Nicolè, Lorenzo, Cappellesso, Rocco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6877753/ https://www.ncbi.nlm.nih.gov/pubmed/31803624 http://dx.doi.org/10.3389/fonc.2019.01255

Ejemplares similares

Editorial: Oncogenic RAS-Dependent Reprogramming of Cellular Plasticity
por: Konstantinidou, Georgia, et al.
Publicado: (2020)

Editorial: Cellular and Phenotypic Plasticity in Cancer
por: Ferrao, Petranel T., et al.
Publicado: (2015)

Tumor Budding in Upper Gastrointestinal Carcinomas
por: Koelzer, Viktor H., et al.
Publicado: (2014)

Perspectives in the Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer Patients
por: Rosati, Gerardo, et al.
Publicado: (2021)

Cellular Phenotype Plasticity in Cancer Dormancy and Metastasis
por: Yang, Xiao, et al.
Publicado: (2018)

Concurrent RAS and RAS/BRAF V600E Variants in Colorectal Cancer: More Frequent Than Expected? A Case Report
por: Zelli, Veronica, et al.
Publicado: (2022)

Genomic landscape and survival analysis of ctDNA “neo-RAS wild-type” patients with originally RAS mutant metastatic colorectal cancer
por: Nicolazzo, Chiara, et al.
Publicado: (2023)

Editorial: The Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer: Challenges and Perspectives
por: Ottaiano, Alessandro, et al.
Publicado: (2022)

Energy Metabolic Plasticity of Colorectal Cancer Cells as a Determinant of Tumor Growth and Metastasis
por: Reinsalu, Leenu, et al.
Publicado: (2021)

Liquid Biopsies in Progressing Metastatic Colorectal Cancer- Application and their Therapeutic Implications According to the RAS Status
por: Pereira, José, et al.
Publicado: (2020)

Editorial: Epigenetics and cellular plasticity in glioblastoma
por: Lo, Hui-Wen, et al.
Publicado: (2023)

Efficacy of third-line anti-EGFR-based treatment versus regorafenib or trifluridine/tipiracil according to primary tumor site in RAS/BRAF wild-type metastatic colorectal cancer patients
por: Salvatore, Lisa, et al.
Publicado: (2023)

Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: Tumor budding as oncotarget
por: Zlobec, Inti, et al.
Publicado: (2010)

Implications of Epithelial–Mesenchymal Plasticity for Heterogeneity in Colorectal Cancer
por: Pereira, Lloyd, et al.
Publicado: (2015)

Development of a Multicellular 3D Tumor Model to Study Cellular Heterogeneity and Plasticity in NSCLC Tumor Microenvironment
por: Arora, Leena, et al.
Publicado: (2022)

Evolution of RAS Mutational Status in Liquid Biopsies During First-Line Chemotherapy for Metastatic Colorectal Cancer
por: Klein-Scory, Susanne, et al.
Publicado: (2020)

Evaluating the Optimal Sequence of Treatment With EGFR Inhibitors and Bevacizumab in RAS Wild-Type Metastatic Colorectal Cancer
por: Martins, Diana, et al.
Publicado: (2022)

HER2 Status in RAS and BRAF Wild-Type Metastatic Colorectal Cancer: A Portuguese Study
por: Fraga, Teresa, et al.
Publicado: (2023)

Tumor budding cells, cancer stem cells and epithelial-mesenchymal transition-type cells in pancreatic cancer
por: Karamitopoulou, Eva
Publicado: (2013)

Emerging roles of endoplasmic reticulum stress in the cellular plasticity of cancer cells
por: Wang, Hao, et al.
Publicado: (2023)

Establishment and Clinical Application of an Artificial Intelligence Diagnostic Platform for Identifying Rectal Cancer Tumor Budding
por: Liu, Shanglong, et al.
Publicado: (2021)

Tumor budding as a predictor for prognosis and therapeutic response in gastric cancer: A mini review
por: Xue, Chi, et al.
Publicado: (2023)

FOLFOXIRI/Bevacizumab Plus Nivolumab as First-Line Treatment in Metastatic Colorectal Cancer RAS/BRAF Mutated: Safety Run-In of Phase II NIVACOR Trial
por: Damato, Angela, et al.
Publicado: (2021)

RAS as Supporting Actor in Breast Cancer
por: Galiè, Mirco
Publicado: (2019)

RIPK3 and AXL Expression Study in Primary Cutaneous Melanoma Unmasks AXL as Predictor of Sentinel Node Metastasis: A Pilot Study
por: Nicolè, Lorenzo, et al.
Publicado: (2021)

The Role of the Extracellular Matrix and Its Molecular and Cellular Regulators in Cancer Cell Plasticity
por: Poltavets, Valentina, et al.
Publicado: (2018)

Recent Advances in Cancer Plasticity: Cellular Mechanisms, Surveillance Strategies, and Therapeutic Optimization
por: Fanelli, Giuseppe Nicolò, et al.
Publicado: (2020)

Breast Cancer Classification Based on Tumor Budding and Stem Cell-Related Signatures Facilitate Prognosis Evaluation
por: Xiang, Zhenxian, et al.
Publicado: (2022)

Exploring Better Strategies for RAS Mutation-Associated EGFR-Targeted Resistance in Colorectal Cancer: From the Perspective of Cancer Community Ecology
por: Wang, Xiaojie, et al.
Publicado: (2021)

EPDR1 levels and tumor budding predict and affect the prognosis of bladder carcinoma
por: Yang, Yue, et al.
Publicado: (2022)

Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice
por: Ottaiano, Alessandro, et al.
Publicado: (2019)

Why the Therapeutic Impact of RAS Mutation Clearance in Plasma ctDNA Deserves to Be Further Explored in Metastatic Colorectal Cancer
por: Nicolazzo, Chiara, et al.
Publicado: (2019)

Cost-Effectiveness of Anti-Epidermal Growth Factor Receptor Therapy Versus Bevacizumab in KRAS Wild-Type (WT), Pan-RAS WT, and Pan-RAS WT Left-Sided Metastatic Colorectal Cancer
por: Lee, Shing Fung, et al.
Publicado: (2021)

Ras recruits mitotic exit regulator Lte1 to the bud cortex in budding yeast
por: Yoshida, Satoshi, et al.
Publicado: (2003)

Molecular and Pathogenetic Aspects of Tumor Budding in Colorectal Cancer
por: Dawson, Heather, et al.
Publicado: (2015)

Role of Epithelial-Mesenchymal Transition in Pancreatic Ductal Adenocarcinoma: Is Tumor Budding the Missing Link?
por: Karamitopoulou, Eva
Publicado: (2013)

Refining the ITBCC tumor budding scoring system with a “zero-budding” category in colorectal cancer
por: Zlobec, Inti, et al.
Publicado: (2021)

Pharmacological Inhibition and Genetic Knockdown of BCL9 Modulate the Cellular Landscape of Cancer-Associated Fibroblasts in the Tumor-Immune Microenvironment of Colorectal Cancer
por: Yang, Mengxuan, et al.
Publicado: (2021)

Androgen Receptor Signaling and Metabolic and Cellular Plasticity During Progression to Castration Resistant Prostate Cancer
por: Uo, Takuma, et al.
Publicado: (2020)

Ferroptosis: A Specific Vulnerability of RAS-Driven Cancers?
por: Andreani, Cristina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0knq19r559u1jgg65fi6ram13j